The strategic session ‘Development of Cardiodiagnostic Products: From Sequencing to Medical Practice’ was recently held at HSE University. The event focused on identifying the market requirements for technology and products developed in the field of genetic testing for cardiovascular diseases.
An international group of scientists and medical specialists, including HSE researchers, examined the role played by microRNA (miRNA) and long non-coding RNAs on the progression of ovarian cancer. Having analysed more than a hundred tumour samples, they found that miRNA can prevent cell mutation while long non-coding RNAs have the opposite effect of enabling such mutations. These findings can help design new drugs which act by regulating miRNA concentrations. The study was published in the International Journal of Molecular Sciences.